As one of the first rate-limiting enzymes in HBP, GFPT1 overexpression is associated with a poor prognosis in prostate cancer (Itkonen et al., 2013), colon cancer (Vasconcelos-Dos-Santos et al., 2017), and pancreatic cancer (Yang et al., 2016). Here, GFPT1 is linked to colonic neoplasm.